Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 8 Prefectures to Prepare Lists of Generics Stocked by Regional Pharmacies
August 10, 2009
- Eisai Licenses Drug-Eluting Bead Products from Biocompatibles
August 10, 2009
- JPMA to Propose Fee-for-Service for Clinical Trials
August 10, 2009
- 4 Cases of Incomplete Artificial Ventilator Connections Reported
August 10, 2009
- R&D NEWS IN BRIEF
August 10, 2009
- Clozaril for Treatment-Resistant Schizophrenia: Novartis
August 10, 2009
- Market for Class 1 OTC Drugs Should Expand in a Few Years: Mr Tokita
August 10, 2009
- Kowas Livalo Approved in US
August 10, 2009
- Miripla Recommended for Approval for Hepatic Cancer
August 10, 2009
- SSP Revises Business Forecasts Upward
August 10, 2009
- Onglyza Approved by FDA as 2nd DPP-4 Inhibitor
August 10, 2009
- Drug Price Maintenance System Necessary: Dr Nishijima of LDP
August 10, 2009
- Draft Position Paper Released on BRONJ and Treatment with Bisphosphonates
August 10, 2009
- DPJ Supports Promotion of the Use of Generics: Dr Adachi
August 10, 2009
- SMUD to Become Operational to Monitor Use of Thalidomide Imported for Personal Use
August 10, 2009
- JPA Vice President Conditionally Supports Industry-Proposed Pricing System Reform
August 10, 2009
- Diabetes and Osteoporosis Are Related: Prof. Okazaki
August 10, 2009
- Industry Must Give Clearer Explanations about Need for NHI Pricing System Reform: Mr Kinoshita
August 10, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 10, 2009
- Marketing Authorization Holders Must Maintain Close Communication with Suppliers
August 10, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…